DrugBiological
Talimogene laherparepvec clinical trials
Also written Imlygic, JS1 34.5-hGMCSF 47- pA- and ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene.
- studies test it
- 41
- open now
- 2
- in phase 3
- 4
- first study started
- 2005
Keep track of what changes. Save the talimogene laherparepvec studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
41 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 8 |
| 2020 | 5 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 18
- Phase 2
- 24
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 17
Who runs them
Industry 16 · Other 25
Amgen (10) · BioVex Limited (6) · National Cancer Institute (NCI) (4) · John Rieth (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Memorial Sloan Kettering Cancer Center (1) · SOLTI Breast Cancer Research Group (1) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Pembrolizumab (5) · Nivolumab (3) · Atezolizumab (2) · Panitumumab (1) · Ipilimumab (1) · Trametinib (1)
Studies
Open first, then newest update. How each study uses talimogene laherparepvec is read from its arms, and is right about nine times in ten.
Testing it · 41
- Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1RecruitingPhase 1Johns Hopkins UniversityNCT07102394Written as Imlygic
- Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingPhase 2University of LouisvilleNCT03842943Written as Talimogene Laherparepvec
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02923778Written as Talimogene Laherparepvec
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02978625Written as Talimogene Laherparepvec
- Neoadjuvant Intralesional Injection of Talimogene LaherparepvecActive, not recruitingPhase 2John RiethNCT06660810Written as Talimogene Laherparepvec
- A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03069378Written as Talimogene Laherparepvec (T-VEC)
- Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02965716Written as Talimogene Laherparepvec
- Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerCompletedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT02779855Written as Talimogene laherparepvec
- TVEC and Preop Radiation for Sarcoma (8 ml Dose)Active, not recruitingPhase 1/2John RiethNCT04599062Written as Talimogene Laherparepvec
- Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the SkinTerminatedPhase 1Rutgers, The State University of New JerseyNCT04163952Written as Talimogene Laherparepvec
- Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedEarly Phase 1SOLTI Breast Cancer Research GroupNCT03802604Written as Talimogene laherparepvec
- Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedPhase 2The Netherlands Cancer InstituteNCT04330430Written as T-VEC
- Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedPhase 2AmgenNCT04068181Written as Talimogene laherparepvec
- Study of Talimogene Laherparepvec (T-VEC) in Pancreatic CancerCompletedPhase 1Karie D. Runcie, MDNCT03086642Written as Talimogene laherparepvec
- Talimogene Laherparepvec for the Treatment of Peritoneal Surface MalignanciesCompletedPhase 1Dan Blazer III, M.D.NCT03663712Written as Talimogene Laherparepvec
- TVEC and Preop Radiation for Sarcoma (4 ml Dose)CompletedPhase 1/2University of IowaNCT02453191Written as Talimogene Laherparepvec
- Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerTerminatedPhase 1National Cancer Institute (NCI)NCT03300544Written as Talimogene Laherparepvec
- Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedPhase 1AmgenNCT03256344Written as Talimogene Laherparepvec
- Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaCompletedPhase 1/2AmgenNCT01740297Written as Talimogene laherparepvec
- Study of Talimogene Laherparepvec In Children With Advanced Non CNS TumorsCompletedPhase 1AmgenNCT02756845Written as Talimogene Laherparepvec
See all 41 studies that test talimogene laherparepvec →
Given in every arm · 5 — talimogene laherparepvec is usual care beside what is tested
- Talimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaRecruitingPhase 2Sarcoma Oncology Research Center, LLCNCT03886311Written as Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedPhase 1University of California, San FranciscoNCT03554044Written as Talimogene Laherparepvec
- A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02819843Written as TALIMOGENE LAHERPAREPVEC (TVEC)
- Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611CompletedPhase 1/2AmgenNCT02509507Written as Talimogene Laherparepvec
- Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaStatus unknownPhase 1West Cancer CenterNCT03088176Written as Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
Codes
What other systems call talimogene laherparepvec · ClinicalTrials.gg INT001044
- MeSH (NLM) C000629782talimogene laherparepvecConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 07730V90L6TALIMOGENE LAHERPAREPVECConfirmed FDA, Wikidata
- RxNorm 1721264Confirmed FDA, Wikidata
- Wikidata Q7679524talimogene laherparepvecConfirmed FDA, Wikidata
- NCI Thesaurus C61314Talimogene LaherparepvecOne source FDA
- DrugBank DB13896One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629782 | talimogene laherparepvec | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 07730V90L6 | TALIMOGENE LAHERPAREPVEC | Confirmed FDA, Wikidata |
| RxNorm | 1721264 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7679524 | talimogene laherparepvec | Confirmed FDA, Wikidata |
| NCI Thesaurus | C61314 | Talimogene Laherparepvec | One source FDA |
| DrugBank | DB13896 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.